7+ search results for 'Guangshengtang'.

Guangshengtang: Covid oral drug GST-HG171 was approved for clinical trials

2022-09-26: Final update: 2022-09-25 21:55:24 According to the WeChat No. “Hongsong Hall Services”, on 25 September, the Anti-Covid-19 oral drug project, developed by the controlled subsidiary of the listed company Hirosheng Hall, was officially entered into the clinical trial phase with the approval of the National

 
GUANCHA 2 months ago 1 minute read

 

Guangshengtang: Covid oral drug GST-HG171 was approved for clinical trials

2022-09-26: Final update: 2022-09-25 21:55:24 According to the WeChat No. “Hongsong Hall Services”, on 25 September, the Anti-Covid-19 oral drug project, developed by the controlled subsidiary of the listed company Hirosheng Hall, was officially entered into the clinical trial phase with the approval of the National  

 
GUANCHA 2 months ago 1 minute read

 

Guangshengtang: Covid oral drug GST-HG171 was approved for clinical trials

2022-09-26: Final update: 2022-09-25 21:55:24 According to the WeChat No. “Hongsong Hall Services”, on 25 September, the Anti-Covid-19 oral drug project, developed by the controlled subsidiary of the listed company Hirosheng Hall, was officially entered into the clinical trial phase with the approval of the National  

 
GUANCHA 2 months ago 1 minute read

 

Guangshengtang: Novel Coronavirus Oral Small Molecule Innovative Drug GST-HG171 Approved for Clinical Trials

2022-09-26: The company e News, Open House (300436) was announced in the evening of 25 September that on 23 September the company's Innovative Drug Control Company, Inc., received from the National Pharmacy Authority, a circular on the approval of clinical trials for drugs for the innovative drug GST-HG171, an oral  

 
TOUTIAO 2 months ago 1 minute read

 

The latest announcement of Guangshengtang: the Covid oral drug GST-HG171 has obtained the clinical trial approval notice

2022-09-26: The Open Life Hall announcement that the Holding Company has received a key milestone in the development of innovative drug research and development for Covid-19 drugs from the National Drug Supervisory Authority (NDSA) for the approval of an innovative drug, GST-HG171, such as an oral small molecule

 
TOUTIAO 2 months ago 1 minute read

 

Guangshengtang (300436.SZ): The Covid oral drug GST-HG171 has been approved for clinical trials with high viral inhibitory activity against multiple strains

2022-09-26: On 23 September 2022, the National Drug Supervisory Authority (NDSA) received a Notice of Approval for the Clinical Trial of Medicines (GST-HG171), an innovative drug such as APP News, Open Life Hall (300436.SZ), the company's Innovative Medicines Control Company, Fujian Guangzhengi Biotech Ltd. (“Hwangashi”)

 
TOUTIAO 2 months ago 1 minute read

 

The chief operating officer of Guangshengtang's anti-Covid oral drug clinical trial was approved: it will have a production capacity of 60 million copies

2022-09-26: Significant progress has been made in the development of anti-Covid-19 oral drugs in the Open House (300436). On the evening of 25 September, the Open House issued an announcement that the innovative drug control subsidiary Fujian Guangsheng Biotech Co. Ltd. (hereinafter referred to as Hiroshi) had

 
TOUTIAO 2 months ago 1 minute read

 

Load More

What China Reads


7+ search results for 'Guangshengtang'.

Guangshengtang: Covid oral drug GST-HG171 was approved for clinical trials

2022-09-26: Final update: 2022-09-25 21:55:24 According to the WeChat No. “Hongsong Hall Services”, on 25 September, the Anti-Covid-19 oral drug project, developed by the controlled subsidiary of the listed company Hirosheng Hall, was officially entered into the clinical trial phase with the approval of the National


GUANCHA 2 months ago 1 minute read

 

Guangshengtang: Covid oral drug GST-HG171 was approved for clinical trials

2022-09-26: Final update: 2022-09-25 21:55:24 According to the WeChat No. “Hongsong Hall Services”, on 25 September, the Anti-Covid-19 oral drug project, developed by the controlled subsidiary of the listed company Hirosheng Hall, was officially entered into the clinical trial phase with the approval of the National  


GUANCHA 2 months ago 1 minute read

 

Guangshengtang: Covid oral drug GST-HG171 was approved for clinical trials

2022-09-26: Final update: 2022-09-25 21:55:24 According to the WeChat No. “Hongsong Hall Services”, on 25 September, the Anti-Covid-19 oral drug project, developed by the controlled subsidiary of the listed company Hirosheng Hall, was officially entered into the clinical trial phase with the approval of the National  


GUANCHA 2 months ago 1 minute read

 

Guangshengtang: Novel Coronavirus Oral Small Molecule Innovative Drug GST-HG171 Approved for Clinical Trials

2022-09-26: The company e News, Open House (300436) was announced in the evening of 25 September that on 23 September the company's Innovative Drug Control Company, Inc., received from the National Pharmacy Authority, a circular on the approval of clinical trials for drugs for the innovative drug GST-HG171, an oral  


TOUTIAO 2 months ago 1 minute read

 

The latest announcement of Guangshengtang: the Covid oral drug GST-HG171 has obtained the clinical trial approval notice

2022-09-26: The Open Life Hall announcement that the Holding Company has received a key milestone in the development of innovative drug research and development for Covid-19 drugs from the National Drug Supervisory Authority (NDSA) for the approval of an innovative drug, GST-HG171, such as an oral small molecule


TOUTIAO 2 months ago 1 minute read

 

Guangshengtang (300436.SZ): The Covid oral drug GST-HG171 has been approved for clinical trials with high viral inhibitory activity against multiple strains

2022-09-26: On 23 September 2022, the National Drug Supervisory Authority (NDSA) received a Notice of Approval for the Clinical Trial of Medicines (GST-HG171), an innovative drug such as APP News, Open Life Hall (300436.SZ), the company's Innovative Medicines Control Company, Fujian Guangzhengi Biotech Ltd. (“Hwangashi”)


TOUTIAO 2 months ago 1 minute read

 

The chief operating officer of Guangshengtang's anti-Covid oral drug clinical trial was approved: it will have a production capacity of 60 million copies

2022-09-26: Significant progress has been made in the development of anti-Covid-19 oral drugs in the Open House (300436). On the evening of 25 September, the Open House issued an announcement that the innovative drug control subsidiary Fujian Guangsheng Biotech Co. Ltd. (hereinafter referred to as Hiroshi) had


TOUTIAO 2 months ago 1 minute read

 

Load More